Monograph Details
|
|
Infections & Infestations
> Bacterial infections
|
|
CUBICIN |
| Manufacturer |
|
Cubist Pharmaceuticals, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Cyclic lipopeptide. |
| Generic Name |
|
Daptomycin 500mg/vial; lyophilized pwd for IV infusion after reconstitution and dilution; preservative-free. |
| Indications |
|
Susceptible complicated skin and skin structure infections, and S. aureus bacteremia including MRSA and MSSA right-sided endocarditis. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
Give by IV infusion over 30 minutes. Skin and skin structure: 4mg/kg once every 24 hours for 7–14 days. S. aureus bacteremia: 6mg/kg once every 24 hours for at least 2–6 weeks. Renal impairment (CrCl <30mL/min): increase dosing interval to once every 48 hours; coincide dose for after dialysis. |
| Precautions |
|
Monitor CPK weekly; discontinue if CPK (≥5xULN) and myopathy occur, or if CPK (≥10xULN) without myopathy occurs. Monitor for neuropathy. Severe hepatic impairment. Elderly. Pregnancy (Cat.B). Nursing mothers. |
| Interactions |
|
Consider suspending statins. Caution with tobramycin. Monitor warfarin. |
| Adverse Reactions |
|
GI disturbances, inj site reactions, headache, insomnia, rash, abnormal liver function tests, elevated CPK, pruritus, urinary tract infection, dizziness, hyper- or hypotension, renal failure, anemia, dyspnea, limb pain. |
| How Supplied |
|
Single-use vials—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
